Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histrelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.76 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | APLNR | P35414 | 5/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histrelin SCHEMBL7619565 | 1.00 | GNRHR (0.77) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29405757 | 1.00 | GNRHR (0.77) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL17881 | 1.00 | GNRHR (0.77) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29372688 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL5327685 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL18715 | 0.99 | ABCC2 (0.78) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL22288995 | 0.94 | GNRHR (0.67) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL1650282 | 0.94 | GNRHR (0.67) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.93 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL7751433 | 0.93 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | claimed |
| US-20190161556-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2019-05-30 | — | — | US | claimed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | claimed |
| US-9278925-B2 | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-08 | — | — | US | claimed |
| CN-105254634-A | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP | 2016-01-20 | — | — | CN | claimed |
| US-8859572-B2 | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | claimed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | claimed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | claimed |
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | claimed |
| CN-101010315-A | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2007-08-01 | — | — | CN | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| WO-2007059202-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | WO | claimed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | claimed |
| CN-1839126-A | Novel cyanopyridine derivatives for the treatment of cancer and other disorders | BAYER PHARMACEUTICALS CORP (US) | 2006-09-27 | — | — | CN | claimed |
| JP-2006519264-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | GNRHR 3818/4885ABCC2 2549/4885PTGS1 1096/4885 |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | VHL, HCCS, CDK4 | GNRHR 3983/4885ABCC2 648/4885PTGS1 820/4885 |
| US-20190161556-A1 | Fusion Protein Construct | RPS27A, CD2BP2, JMJD7 | GNRHR 3550/4885ABCC2 4453/4885PTGS1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.